1
EXHIBIT 10.17
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
CLINICAL TRIAL SERVICES AGREEMENT
---------------------------------
THIS CLINICAL TRIAL SERVICES AGREEMENT (the "Agreement"), made as of
September 23, 1997, by and between ▇▇▇▇▇▇ INTERNATIONAL INC., a corporation
with principal offices at 700 ▇▇▇▇▇ Tower, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇
▇▇▇▇▇-▇▇▇▇ ("▇▇▇▇▇▇") and ▇. ▇. ▇▇▇▇▇▇ & CO., a Delaware corporation with
principal offices at ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇.▇.▇.
("▇▇▇▇▇▇").
WITNESSETH:
-----------
WHEREAS, ▇▇▇▇▇▇ is engaged in the business of managing, monitoring and
coordinating multi-site clinical research programs; and
WHEREAS, ▇▇▇▇▇▇ desires ▇▇▇▇▇▇ to manage, monitor and coordinate
various research programs, and ▇▇▇▇▇▇ is willing to provide such services
subject to the terms hereof.
WHEREAS, ▇▇▇▇▇▇ proposes to retain ▇▇▇▇▇▇ as a preferred provider and
recognized expert to work in a close professional relationship with ▇▇▇▇▇▇ to
assist in the worldwide development of its Pharmaceutical Products.
NOW, THEREFORE, the parties agree as follows:
ARTICLE 1 -- DEFINITIONS
------------------------
1.1 "ACT" shall mean the United States Food, Drug, and Cosmetic Act, as
amended, and any and all rules and regulations promulgated thereunder.
-1-
2
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
1.2 "CASE REPORT FORMS" shall mean the Case Report Forms developed and/or
approved by ▇▇▇▇▇▇ which are to be used by the Investigators (as
hereinafter defined) to record data from the Study (as hereinafter
defined).
1.3 "ELIGIBLE PATIENT" shall mean any patient who meets the
inclusion/exclusion criteria for participation in the Study which are
set forth in the Protocol (as hereinafter defined), signs an acceptable
Patient Informed Consent Form and participates in the Study.
1.4 "EVALUABLE PATIENT" shall mean an eligible Patient who meets the
criteria in the Protocol which must be met and documented on a Case
Report Form in order to be judged evaluable for analysis.
1.5 EXHIBIT" shall mean a mutually approved written description of the
Services that ▇▇▇▇▇▇ will provide for a given Study, the manpower and
financial resources that ▇▇▇▇▇▇ will use to provide those Services, the
milestones that ▇▇▇▇▇▇ must achieve before they will invoice ▇▇▇▇▇▇ for
the Services, and the invoice amounts that will be associated with each
of those milestones.
1.6 "FDA" shall mean the United States Food and Drug Administration or any
successor entity thereto.
1.7 "INVESTIGATOR" shall mean a licensed physician, Ph.D., or Pharm.D.
engaged by ▇▇▇▇▇▇ or ▇▇▇▇▇▇ to conduct the Study.
1.8 "IRB" shall mean the Institutional Review Board(s) organized in
accordance with the Act.
1.9 "PROTOCOL" shall mean the various protocols that will be incorporated
herein by this reference, and any amendments thereto.
-2-
3
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
1.10 "SITE" shall mean the physical location at which a particular
Investigator conducts the Study.
1.11 "STUDY" shall mean the clinical research described in the Protocol.
1.12 "STUDY MEDICATION" shall mean the pharmaceutical compound that is the
subject of the Study.
ARTICLE 2 -- SERVICES OF CONTRACTOR
-----------------------------------
2.1 PURPOSE. ▇▇▇▇▇▇ hereby retains ▇▇▇▇▇▇, and ▇▇▇▇▇▇ agrees to assist
▇▇▇▇▇▇ in the management and monitoring of a series of Studies in
accordance with the Protocol identified in the Exhibit.
2.2 SPECIFIC SERVICES.
(a) ▇▇▇▇▇▇ will provide ▇▇▇▇▇▇ with clinical, regulatory, data
management, biostatistics, pharmacoeconomics outcomes
research, medical consulting, medical writing, management and
systems, and products and consulting services specified herein
and in each Exhibit (collectively, the Services"). These
Services may include, but are not limited to the following: 1)
management consulting regarding staffing and capacity
optimization, work flow improvement, productivity management,
organizational design, standard operating procedures and
training; 2) working with ▇▇▇▇▇▇ to design and implement cost
effective strategies and methods to establish convenient
electronic data communication links between ▇▇▇▇▇▇ and ▇▇▇▇▇▇;
and 3) working with ▇▇▇▇▇▇ to define compatible, mutually
beneficial information
-3-
4
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
systems approaches for performing basic clinical research
operations and to provide relevant applications to support
▇▇▇▇▇▇ research and development activities. ▇▇▇▇▇▇ management
shall be readily accessible to facilitate optimal management
of individual projects and to provide general management
consulting support.
(b) The Services shall be provided on a project-by project basis
and in accordance with the terms of each Exhibit (which shall
be subject to the mutual agreement of the parties). Prior to
commencing any Services relating to a particular Exhibit, the
parties shall each sign such Exhibit which shall be attached
to this Agreement and made a part hereof.
(c) Each project shall be governed by the terms and conditions of
this Agreement and by supplementary written amendments to this
Agreement, if any, and such Exhibits or Schedules as may be,
from time to time, executed between the parties. In the event
of a conflict between the terms of this Agreement and an
Exhibit or Schedule, the terms of this Agreement shall govern.
(d) If ▇▇▇▇▇▇ wishes to change the scope of the Services covered
by a specific Exhibit to this Agreement or wishes to obtain
additional Services not initially covered by said Exhibit,
▇▇▇▇▇▇ shall so advise ▇▇▇▇▇▇ and shall submit specifications
to ▇▇▇▇▇▇. After receipt of the specifications, ▇▇▇▇▇▇ shall
provide ▇▇▇▇▇▇ with a cost estimate for performing the changed
or additional Services. If such cost estimate is accepted by
▇▇▇▇▇▇, the parties shall
-4-
5
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
execute an authorization for Additional Work and, thereafter,
▇▇▇▇▇▇ shall commence performance of the changed or additional
Services.
2.3 RECORDS. ▇▇▇▇▇▇ shall maintain complete and accurate records of each
visit to a Site and any and all other records and information relating
to the conduct of the Study or the performance of the Services which
may be required by the Act or any other law or regulation. Such records
shall be maintained for a period of three (3) years from the date
hereof or such longer period as may be required by law. At the end of
such retention period, ▇▇▇▇▇▇ shall offer all such records to ▇▇▇▇▇▇ by
written notice. If within thirty (30) days of such notice, ▇▇▇▇▇▇ does
not notify ▇▇▇▇▇▇ to ship such records to ▇▇▇▇▇▇, at ▇▇▇▇▇▇'▇ expense,
▇▇▇▇▇▇ shall promptly destroy same and certify in writing to ▇▇▇▇▇▇
that such destruction has occurred.
2.4 AUDIT RIGHT. The records described in Section 2.3 above shall be made
available to ▇▇▇▇▇▇ at ▇▇▇▇▇▇'▇ request and to the FDA at the FDA's
request for inspection, copying and audit at any time with reasonable
notice during the term hereof and during the retention period described
above. Any expense associated with such a request by ▇▇▇▇▇▇ for
inspection, copying and/or audit will be the responsibility of ▇▇▇▇▇▇.
2.5 VISITS BY REGULATORY AGENCIES. ▇▇▇▇▇▇ shall notify ▇▇▇▇▇▇ immediately
by telephone (followed by written confirmation) of any proposed or
actual visit by FDA representatives to ▇▇▇▇▇▇'▇ offices or to any Site.
2.6 RESOLUTION OF DISPUTES AND DEFICIENCIES. Any deficiencies noted by
▇▇▇▇▇▇ in the Services performed by ▇▇▇▇▇▇ or in the conduct of the
Study by any Investigator
-5-
6
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
shall be resolved by ▇▇▇▇▇▇ to the reasonable satisfaction of ▇▇▇▇▇▇.
In the event of any disputes between ▇▇▇▇▇▇ and ▇▇▇▇▇▇, the parties
shall make good faith efforts to resolve any such dispute as promptly
as possible.
2.7 TRANSFER OF RESPONSIBILITIES.
(a) Pursuant to 21 Code of Federal Regulations ("CFR")
Part 312.52, ▇▇▇▇▇▇ hereby transfers to ▇▇▇▇▇▇ and ▇▇▇▇▇▇
hereby assumes from ▇▇▇▇▇▇, the responsibility for those
services that will be described in an Exhibit and accordingly,
▇▇▇▇▇▇ shall be responsible for performance of all such
obligations as contemplated in said Part of the CFR.
(b) Notwithstanding the foregoing, it is understood that ▇▇▇▇▇▇
shall be responsible for any obligations of clinical study
sponsors which are set forth in the Act and not specifically
transferred to ▇▇▇▇▇▇ under Section 2.7(a).
ARTICLE 3 -- STANDARD OF PERFORMANCE, STAFFING AND RECORDS
----------------------------------------------------------
3.1 STANDARD OF PERFORMANCE. ▇▇▇▇▇▇ shall perform the Services and all of
its other obligations set forth herein and in any Exhibit in strict
accordance with:
(a) all applicable statutes, rules and regulations, including
without limitation the Act and any proposed FDA regulations
provided by ▇▇▇▇▇▇;
(b) the Protocol;
(c) the mandates of the IRB approving the Study;
(d) the SOPs (as defined in Section 3.2); and
(e) any other instructions from ▇▇▇▇▇▇.
-6-
7
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
▇▇▇▇▇▇ shall also perform the Services in a competent and professional
manner, consistent with the current state of clinical research and
current good clinical practices acceptable to the FDA. ▇▇▇▇▇▇ shall, as
necessary, consult with ▇▇▇▇▇▇ on matters regarding safety
considerations and Study implementation, and will adhere to ▇▇▇▇▇▇'▇
advice concerning same.
3.2 SOPS. ▇▇▇▇▇▇ shall make available to ▇▇▇▇▇▇ for its review ▇▇▇▇▇▇'▇
standard operating procedures (SOPs) relating to the Services during
the time that this Agreement is in effect.
3.3 STAFFING.
(a) ▇▇▇▇▇▇ shall be responsible for providing all personnel
required to perform the Services, as well as any necessary
replacements. ▇▇▇▇▇▇ shall use all reasonable efforts to
provide qualified individuals to fill such positions. ▇▇▇▇▇▇
shall also give due consideration to the advice of ▇▇▇▇▇▇ with
respect to the decision to use, or to continue or discontinue
the use of, specific personnel for purposes of the conduct of
Study monitoring, programming and statistical analysis. ▇▇▇▇▇▇
shall not engage any subcontractor to perform or assist in the
performance of the Services without the prior notification of
▇▇▇▇▇▇. ▇▇▇▇▇▇ retains the right to request removal of that
person from our projects.
(b) ▇▇▇▇▇▇ shall not use any person (including Investigators)
debarred by the FDA in any capacity in connection with the
performance of the Services or the Study. Upon the execution
of this Agreement, ▇▇▇▇▇▇ shall provide
-7-
8
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
▇▇▇▇▇▇ with the certification attached hereto as Attachment A
in each Exhibit.
(c) ▇▇▇▇▇▇ will provide ▇▇▇▇▇▇, on request, a list of all
employees, subcontractors, agents or representatives used in
any capacity in connection with the Services who have been
convicted of any of the following within the past six years:
(i) Any felony or misdemeanor under Federal law or felony
under State law for conduct relating to the
development or approval, including the process for
development or approval, of any drug product, or
otherwise relating to the regulation of drug products
under the Federal Food, Drug, and Cosmetic Act;
(ii) Any other felony that involves bribery, payment of
illegal gratuities, fraud, perjury, false statement,
racketeering, blackmail, extortion, falsification or
destruction of records, or interference with,
obstruction of an investigation into, or prosection
of, any criminal offense; or
(iii) A conspiracy to commit, or aiding or abetting, any
offense contained in paragraphs (I) or (ii).
3.4 ACCURATE INFORMATION. ▇▇▇▇▇▇ hereby represents to ▇▇▇▇▇▇ that ▇▇▇▇▇▇
shall take all reasonably necessary steps to assure that all data,
reports, forms or any other records generated pursuant to the Study by
▇▇▇▇▇▇, its agents, employees,
-8-
9
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
subcontractors or representatives or by Investigators shall be true and
accurate and shall contain no false or misleading information.
ARTICLE 4 -- OBLIGATIONS OF ▇▇▇▇▇▇
----------------------------------
4.1 SUPPLIES TO INVESTIGATORS. Prior to commencing any Services relating to
a particular Exhibit, ▇▇▇▇▇▇ shall provide at its own expense and
directly or indirectly to each investigator, if appropriate:
(a) a copy of the investigational brochure for the Study
Medication, the Protocol and any other written information
required by the Investigator to perform the Study which is not
supplied by ▇▇▇▇▇▇ under Article 2;
(b) supplies of the Study Medication and any other medications
specified in the Protocol; and
(c) a supply of Case Report Forms.
4.2 COMPLIANCE WITH LAW. ▇▇▇▇▇▇ shall comply with all laws and regulations,
including without limitation the Act, which are applicable to ▇▇▇▇▇▇'▇
sponsorship and reporting of the Study.
ARTICLE 5 -- PAYMENTS TO CONTRACTOR
-----------------------------------
5.1 PROFESSIONAL FEE.
-----------------
(a) In consideration for ▇▇▇▇▇▇'▇ performance of the Services,
▇▇▇▇▇▇ shall pay ▇▇▇▇▇▇ with respect to each project the
amount specified in the relevant Exhibit governing each such
project. Should the scope of a project described
-9-
10
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
in any Exhibit change, the fee to be paid by ▇▇▇▇▇▇ under such
Exhibit will be adjusted pursuant to Section 2.2(d).
(b) ▇▇▇▇▇▇ and ▇▇▇▇▇▇ agree that they will jointly utilize all
reasonable efforts to identify and implement cost savings
opportunities throughout the performances of the services.
Savings resulting from these efforts will be passed onto
▇▇▇▇▇▇.
5.2 EXPENSES. ▇▇▇▇▇▇ shall reimburse ▇▇▇▇▇▇ for all of its reasonable
out-of-pocket expenses incurred in connection with its performance of
the Services as set forth in each Exhibit. ▇▇▇▇▇▇ shall not be
reimbursed for expenses in excess of the amount agreed upon in the
relevant Exhibit.
5.3 PAYMENT PROCEDURES.
(a) ▇▇▇▇▇▇ shall invoice ▇▇▇▇▇▇ each calendar month for Services
provided and the expenses incurred during the prior calendar
month in accordance with the schedule of payments set forth in
the relevant Exhibits or Letters of Intent governing each
project, subject to the limitation set forth in each such
Exhibit. ▇▇▇▇▇▇'▇ invoice shall be accompanied by original
receipts or any other supporting information reasonably
satisfactory to ▇▇▇▇▇▇, and shall be sent to:
▇▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Finance and Administration
▇▇▇▇▇▇ Clinical R&D
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Telephone: ▇▇▇-▇▇▇-▇▇▇▇
FAX: ▇▇▇-▇▇▇-▇▇▇▇.
-10-
11
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
(b) ▇▇▇▇▇▇ shall pay ▇▇▇▇▇▇ within thirty (30) days of receipt and
acceptance of invoices; provided they comply with the terms
hereof. Checks shall be made payable to ▇▇▇▇▇▇ International
Inc., Federal I.D. ▇▇-▇▇▇▇▇▇▇, and mailed to:
▇▇. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Controller
▇▇▇▇▇▇ International Inc.
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
5.4 FINAL RECONCILIATION. At the conclusion of the Services for each
Exhibit, ▇▇▇▇▇▇ shall submit to ▇▇▇▇▇▇ a final invoice which shall
include an accounting reconciling all payments made by ▇▇▇▇▇▇ and all
amounts invoiced by ▇▇▇▇▇▇.
5.5 RECORDS AND AUDIT. ▇▇▇▇▇▇ shall keep and maintain complete and accurate
books and records in sufficient detail to determine amounts owed to
▇▇▇▇▇▇ hereunder. Such books and records shall be maintained for at
least two (2) years following completion of the Study or termination of
this Agreement and shall be made available for inspection, copying and
audit by ▇▇▇▇▇▇, upon reasonable notice by ▇▇▇▇▇▇, for the sole purpose
of determining the accuracy of amounts invoiced hereunder. If any such
audit discloses an underpayment or overpayment of amounts due
hereunder, the party owing same shall pay the amount due to the other
party within thirty (30) days of written notice.
-11-
12
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
ARTICLE 6 -- TERM AND TERMINATION
---------------------------------
6.1 TERM. The term of this Agreement shall begin as of the date of the last
signature on this Agreement and shall continue until December 31, 2001.
6.2 EXTENSIONS OF TERM. ▇▇▇▇▇▇ and ▇▇▇▇▇▇ may extend the term of this
Agreement upon mutual written agreement.
6.3 TERMINATION BY ▇▇▇▇▇▇. ▇▇▇▇▇▇ may terminate this Agreement or a project
to be performed pursuant to an Exhibit to this Agreement at any time on
forty-five (45) days prior written notice to ▇▇▇▇▇▇.
6.4 TERMINATION BY EITHER PARTY. In addition to any other rights or
remedies available at law or in equity, this Agreement may be
terminated by either party:
(a) on written notice effective immediately if the other party
commits a material breach of this Agreement which is not cured
within thirty (30) days of receipt of written notice from the
other party; or
(b) on thirty (30) days written notice if the other party becomes
insolvent, is dissolved or liquidated, makes a general
assignment for the benefit of its creditors, files or has
filed against it, a petition in bankruptcy, or has a receiver
appointed for a substantial part of its assets.
6.5 OBLIGATIONS ON EXPIRY OR TERMINATION.
(a) Upon early termination (other than for ▇▇▇▇▇▇'▇ default),
▇▇▇▇▇▇ shall be entitled to a PRO-RATA portion of the
compensation as provided under Article 5, based on the degree
of completion of the Services described in each Exhibit as
-12-
13
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
of the date of termination. ▇▇▇▇▇▇ shall also reimburse ▇▇▇▇▇▇
for any accrued, but unpaid expenses incurred as permitted
under Article 5.
(b) Within thirty (30) days of the expiration or termination of
this Agreement, an Exhibit, or the Study for any reason,
▇▇▇▇▇▇ shall return to ▇▇▇▇▇▇ all completed, partially
completed and unused Case Report Forms and all other materials
in ▇▇▇▇▇▇'▇ possession or control and relating to the Study,
including but not limited to all data (in any form, including
electronic) and other information resulting from the Study or
provided by ▇▇▇▇▇▇.
(c) If this Agreement and/or the Study is prematurely terminated,
▇▇▇▇▇▇ shall conclude the Study as expeditiously as possible
and in accordance with ▇▇▇▇▇▇'▇ reasonable instructions and
all applicable federal, state and local laws, regulations and
guidelines. ▇▇▇▇▇▇ shall use its best efforts to minimize any
expenses resulting from such early termination.
ARTICLE 7 -- INDEMNIFICATION
7.1 INDEMNIFICATION OF ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall defend, indemnify and hold
harmless ▇▇▇▇▇▇ and its directors, officers and employees, from and
against any and all liabilities, costs and expenses (including
reasonable attorneys' fees and court costs) arising from any third
party claim, action, lawsuit or other proceeding to the extent such
liability, cost or expense is attributable to any negligent or willful
act or omission or breach of this Agreement on the part of ▇▇▇▇▇▇ or
any of its employees in the course of performing ▇▇▇▇▇▇'▇ obligations
hereunder; provided however that:
-13-
14
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
(a) ▇▇▇▇▇▇ shall have notified ▇▇▇▇▇▇ within ten (10) working days
after receipt of notice of the claim, action, lawsuit or other
proceeding; and
(b) ▇▇▇▇▇▇ shall fully cooperate in the investigation and defense
of any such claim, action, lawsuit or other proceeding and
shall not agree to any settlement thereof without ▇▇▇▇▇▇'▇
prior written consent.
Notwithstanding the foregoing, ▇▇▇▇▇▇ shall not be required to
indemnify ▇▇▇▇▇▇ for any liability, cost or expense attributable to any
negligent or willful act or omission or breach of this Agreement on the
part of ▇▇▇▇▇▇ or any of its employees, agents, subcontractors or other
representatives of ▇▇▇▇▇▇ in the course of performing its obligations
hereunder.
7.2 INDEMNIFICATION OF ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall defend, indemnify and hold
harmless ▇▇▇▇▇▇ and its directors, officers and employees, from and
against any and all liabilities, costs and expenses (including
reasonable attorneys' fees and court costs) arising from any claim,
action, lawsuit or other proceeding (I) arising out of or in connection
with the conduct of the Study, or (ii) to the extent such liability,
cost or expense is attributable to any negligent or willful act or
omission or breach of this Agreement on the part of ▇▇▇▇▇▇ or any of
its employees in the course of performing ▇▇▇▇▇▇'▇ obligations
hereunder; provided however that:
(a) ▇▇▇▇▇▇ shall have notified ▇▇▇▇▇▇ within ten (10) working days
after receipt of notice of the claim, action, lawsuit or other
proceeding; and
-14-
15
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
(b) ▇▇▇▇▇▇ shall fully cooperate in the investigation and defense
of any such claim, action, lawsuit or other proceeding and
shall not agree to any settlement thereof without ▇▇▇▇▇▇'▇
prior written consent.
Notwithstanding the foregoing, ▇▇▇▇▇▇ shall not be required to
indemnify ▇▇▇▇▇▇ for any liability, cost or expense attributable to any
negligent or willful act or omission or breach of this Agreement on the
part of ▇▇▇▇▇▇ or any of its employees, agents, subcontractors or other
representatives of ▇▇▇▇▇▇ in the course of performing its obligations
hereunder.
7.3 CONFLICTS OF INTEREST.
(a) ▇▇▇▇▇▇ shall have the right to select defense counsel and to
direct the defense or settlement of any claim, action, lawsuit
or other proceeding described in Paragraph 7.2.
(b) ▇▇▇▇▇▇ shall have the right to select defense counsel and to
direct the defense of any claim, action, lawsuit or other
proceeding described in Paragraph 7.1.
7.4 LIMITATION OF DAMAGES. Notwithstanding the foregoing, neither party
shall be liable for any special, indirect, incidental or consequential
damages, including lost profits, incurred by the other party, for any
reason.
ARTICLE 8 -- INSURANCE
8.1 INSURANCE REQUIREMENT. As an independent contractor, ▇▇▇▇▇▇ will carry
the policies of insurance described below for the term of this
Agreement. Such policies shall not be cancelable or subject to material
amendment which would materially and
-15-
16
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
adversely harm ▇▇▇▇▇▇'▇ interests without sixty (60) days' prior
written notice to ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall furnish ▇▇▇▇▇▇ with certificates
of insurance for all such policies before commencing work hereunder and
the General Liability policy shall name ▇▇▇▇▇▇ and its affiliates and
subsidiaries as additional insureds. The type and limits of such
policies shall be as follows:
1) Workmen's Compensation Statutory
2) Employer's Liability $500,000 each person each accident
3) Commercial General Liability $1,000,000 combined limit each
occurrence for Bodily Injury and
Property Damage. This policy must
include blanket contractual
liability coverage.
4) Automobile Liability Bodily Injury and Property Damage
(including Hired $500,000 combined limit each
Automobile and Non- occurrence
Ownership Liability)
ARTICLE 9 -- PROPERTY OWNERSHIP AND RETENTION
---------------------------------------------
9.1 OWNERSHIP. The following materials shall be deemed to be the exclusive
property of ▇▇▇▇▇▇ and are hereinafter collectively referred to as
"▇▇▇▇▇▇ Information":
(a) All materials, documents and information of every kind and
description supplied to ▇▇▇▇▇▇ by ▇▇▇▇▇▇;
(b) All materials, documents and information of every kind and
description prepared or developed by ▇▇▇▇▇▇ pursuant to this
Agreement or an Exhibit, except for procedural manuals, personnel
data and computer software existing at the time of this Agreement;
and
-16-
17
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
(c) All clinical data (including Case Report Forms and the data
contained therein) and reports prepared by any of the
Investigators. Nothing in this paragraph shall preclude the
publishing of the results of any clinical trial(s) by the
Investigators in accordance with the terms of their respective
contracts.
9.2 INVENTIONS AND DISCOVERIES.
------------------------------------
(a) ▇▇▇▇▇▇ will promptly disclose to ▇▇▇▇▇▇ or its nominee any and all
inventions, discoveries and improvements conceived, made or
reduced to practice by ▇▇▇▇▇▇ or any agent, employee,
subcontractor or other representative of ▇▇▇▇▇▇ in the course of
performing the Services. ▇▇▇▇▇▇ hereby agrees to assign all its
right, title and interest therein to ▇▇▇▇▇▇ or its nominee.
(b) Whenever requested to do so by ▇▇▇▇▇▇, ▇▇▇▇▇▇ will execute any and
all applications, assignments or other instruments and give
testimony which ▇▇▇▇▇▇ shall ▇▇▇▇ necessary to apply for and
obtain patent letters of the United States or of any foreign
country or to protect otherwise ▇▇▇▇▇▇'▇ interest therein. ▇▇▇▇▇▇
shall ensure that its contractual arrangements with its agents,
employees, subcontractors and other representatives provide for
their automatic assignment to ▇▇▇▇▇▇ of all such inventions,
discoveries and improvements.
ARTICLE 10 -- CONFIDENTIALITY
-----------------------------
10.1 UNDERTAKING. During the term hereof and for a period of ten (10) years
following the expiration or termination hereof, ▇▇▇▇▇▇ shall keep
confidential and not use (other
-17-
18
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
than to perform the Services) any of the ▇▇▇▇▇▇ Information. ▇▇▇▇▇▇
further agrees to limit disclosure of the ▇▇▇▇▇▇ Information to agents,
subcontractors, employees and other representatives of ▇▇▇▇▇▇ who have
signed agreements with ▇▇▇▇▇▇ reiterating the provisions of this
Article and to Investigators who have signed Investigator Contracts.
10.2 EXCEPTIONS. The obligations set forth in Paragraph 10.1 shall not apply
to ▇▇▇▇▇▇ Information which:
(a) is already known to ▇▇▇▇▇▇ as shown by its prior written records;
(b) is or becomes publicly available through no fault of ▇▇▇▇▇▇;
(c) is received from a third party which ▇▇▇▇▇▇ believes in good faith
has a right to disclose it; or
(d) is required by law to be disclosed.
10.3 PUBLICATIONS. It is expressly understood that neither ▇▇▇▇▇▇ nor any
agent, employee, subcontractor or other representative of ▇▇▇▇▇▇ shall
have the right to publish any information concerning any ▇▇▇▇▇▇ Study.
ARTICLE 11 -- ASSIGNMENT
------------------------
11.1 BY ▇▇▇▇▇▇. ▇▇▇▇▇▇ may not assign, transfer or attempt to assign or
transfer any of its rights or obligations hereunder without the prior
written consent of ▇▇▇▇▇▇. Any attempt by ▇▇▇▇▇▇ without ▇▇▇▇▇▇'▇ prior
written consent shall constitute a material default hereunder.
-18-
19
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
11.2 BY ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall have the right to assign this Agreement, in
whole or in part, on thirty (30) days' prior written notice to ▇▇▇▇▇▇.
ARTICLE 12 -- ENTIRE AGREEMENT; AMENDMENTS
------------------------------------------
12.1 ENTIRE AGREEMENT. This Agreement, together with each Exhibit and each
Protocol, constitutes the entire agreement between the parties with
respect to the subject matter hereof. All projects and contracts
entered into prior to the signing of this Agreement remain in full
force and effect.
12.2 AMENDMENTS. This Agreement may not be amended except in writing signed
by both parties.
ARTICLE 13 -- MISCELLANEOUS
---------------------------
13.1 CONFLICT OF INTEREST. ▇▇▇▇▇▇ represents to ▇▇▇▇▇▇ that it has no
obligations, contractual or otherwise, that would conflict with its
entering into this Agreement or performing the Services and that it
will undertake no such obligations during the term hereof.
13.2 INDEPENDENT CONTRACTOR. ▇▇▇▇▇▇ is an independent contractor and nothing
in this Agreement shall be construed to create a partnership, joint
venture or employment relationship between the parties. ▇▇▇▇▇▇ shall
have no authority to bind ▇▇▇▇▇▇ to any commitment whatsoever, and
▇▇▇▇▇▇ shall not hold itself out to third parties as having authority
to do so.
-19-
20
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
13.3 NOTICES. Any notice which either party may be required to give the
other shall be deemed to be duly given when mailed by certified or
registered mail, postage prepaid, return receipt requested, to the
other party at the addresses first given above, addressed to the
attention of the person signing this Agreement for such party or to
such other addresses and recipients as the parties may direct in
writing. Notices shall be deemed to be effective five (5) days after
mailing.
13.4 SEVERABILITY. If any provision hereof shall be determined to be invalid
or unenforceable, such determination shall not affect the validity of
the other provisions of this Agreement; provided that the parties shall
promptly agree upon replacement provision(s) which approximate as
closely as possible the spirit and intent of the invalid provision(s).
13.5 SURVIVAL. Sections 2.3 (Records), 2.4 (Audit Right), 6.3 (Termination
by ▇▇▇▇▇▇), 6.4 (Termination by Either Party), 6.5 (Obligations on
Expiry or Termination), Articles 7 (Indemnification), Article 9
(Property Ownership and Retention), Article 10 (Confidentiality), shall
survive the expiration or earlier termination of this Agreement.
13.6 GOVERNING LAW. This Agreement shall be governed by and interpreted in
accordance with the laws of the state of Illinois, regardless of its
choice of law principles.
13.7 WAIVERS. Waiver by either party or the failure by either party to claim
a breach of any provision of this Agreement shall not be deemed to
constitute a waiver or estoppel with respect to any subsequent breach
of any provision hereof.
13.8 USE OF NAMES. Each party, on behalf of itself, its agents, employees,
subcontractors and representatives agrees not to use the name of the
other party or its agents,
-20-
21
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
employees, subcontractors and representatives in any publication,
promotional material or other writing or oral statement for public
distribution, relative to the subject matter or existence of this
Agreement, except as otherwise required by law or previously consented
to in writing by the other party. Notwithstanding the foregoing, ▇▇▇▇▇▇
consents to ▇▇▇▇▇▇ advising prospective clients that ▇▇▇▇▇▇ has
performed clinical research services for ▇▇▇▇▇▇.
13.9 FORCE MAJEURE. Either party's failure to perform its obligations
hereunder shall be excused to the extent and for the period of time
such nonperformance is caused by an event of FORCE MAJEURE, including
but not limited to, the occurrence of war, invasion, fire, explosion,
flood, riot, strikes, acts of God, acts of government or governmental
agencies or instrumentalities or contingencies or causes beyond such
party's reasonable control.
IN WITNESS WHEREOF, the parties have executed this Agreement the day and year
set forth above.
▇▇▇▇▇▇ INTERNATIONAL INC. ▇.▇. ▇▇▇▇▇▇ & CO.
By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ By:
-------------------------- ------------------------------
Title: V.P. - C.F.O. Title:
----------------------- ----------------------------
-21-
22
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
LIST OF ATTACHMENTS
-------------------
A Certification
-22-
23
▇▇▇▇▇▇/▇▇▇▇▇▇ Master Agreement
ATTACHMENT A
------------
▇▇▇▇▇▇ hereby certifies that, to the best of its ability and/or knowledge, it
will not or has not employed or otherwise used in any capacity the services of
any person debarred under section 306(a) or (b) of the Federal Food, Drug, and
Cosmetic Act in connection with its activities related to Protocol No. ________
entitled____________________________________________________________.
--------------------------------
▇▇▇▇▇▇ INTERNATIONAL INC
-23